Jane Street’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Jane Street’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,801	Closed	-$19K	–	11524
2021 Q4	$19K	Buy	+13,801	New	+$32.6K	﹤0.01%	9817
2021 Q3	–	Sell	-14,169	Closed	-$49K	–	11154
2021 Q2	$49K	Sell	14,169 -13,909	-50%	-$47.8K	﹤0.01%	9516
2021 Q1	$96K	Buy	+28,078	New	+$531K	﹤0.01%	8665
2020 Q3	–	Sell	-6,071	Closed	-$257K	–	8265
2020 Q2	$257K	Buy	+6,071	New	+$196K	﹤0.01%	6061

Other funds holding ODT

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Jane Street's ODT Position: Q1 2022 in Review

Jane Street sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 13,801 shares — an estimated $19K sold.

Jane Street first reported a position in ODT in Q2 2020 and held it in 4 quarters. The position peaked at $257K in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

Jane Street reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Jane Street sold 13,801 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $19K.
Jane Street first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
Jane Street's Odonate Therapeutics, Inc. Common Stock position peaked at $257K in Q2 2020.
8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Jane Street's 13F filing for Q1 2022, filed 17 May 2022.